Treating glioma CSCs with an Hh signaling inhibitor reduced multiplication, survival, self-renewal, and clonogenicity of the CSCs and diminished expression of stemness genes, such as Nanog, Sox2, and Oct4 [79]. This evidence concerns the gene POU5F1 and central nervous system cancer.